Paolo Ascierto: Pembrolizumab indication extended for neoadjuvant therapy in melanoma
Paolo Ascierto, Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at RCCS National Cancer Institute G. Pascale Foundation, shared a post on LinkedIn:
“Good news! The extension of the indication for Pembrolizumab for neoadjuvant therapy in Melanoma has been published in the Gazzetta Official.
This is an important milestone: consider that neoadjuvant therapy is not reimbursed in most countries, not even in the USA, and this represents a major step forward for our country and, most importantly, for all our patients.
Neoadjuvant therapy is applied to patients with operable lymph node or skin metastases and consists of three cycles of immunotherapy before surgery, followed by continued therapy for an additional 10 months after the surgery.
The extension of the indications comes after a request from several scientific societies, led by AIOM (Italian Association of Medical Oncology) with Melanoma Foundation, IMI – Intergruppo Melanoma Italiano and NIBIT Translational Science.
Read the official document.”
More posts featuring Paolo Ascierto.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023